These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 6546484

  • 1. Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease.
    Takamatsu J, Sugawara M, Kuma K, Kobayashi A, Matsuzuka F, Mozai T, Hershman JM.
    Ann Intern Med; 1984 Mar; 100(3):372-5. PubMed ID: 6546484
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H, Hayaki I, Kawai K, Komaki G, Matsubayashi S, Kuma K, Kumagai LF, Nagataki S.
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A, Yamada T, Aizawa T, Ichikawa K, Komiya I, Takasu N, Takemura Y.
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [Abstract] [Full Text] [Related]

  • 6. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease.
    Takamatsu J, Kuma K, Mozai T.
    J Clin Endocrinol Metab; 1986 May; 62(5):980-3. PubMed ID: 3754263
    [Abstract] [Full Text] [Related]

  • 7. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
    Yamada T, Koizumi Y, Sato A, Hashizume K, Aizawa T, Takasu N, Nagata H.
    J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
    [Abstract] [Full Text] [Related]

  • 8. Value of simultaneous T3, T4, and TSH measurements for management of graves' disease in children.
    Golden MP, Kaplan SA, Lippe BM, Lee WN.
    Pediatrics; 1977 May; 59(5):762-7. PubMed ID: 577011
    [Abstract] [Full Text] [Related]

  • 9. Simple and reliable method for predicting the remission of Graves' disease: revised triiodothyronine-suppression test, indexed by serum thyroxine.
    Takasu N, Akamine H, Komiya I, Yamada T.
    J Endocrinol Invest; 1995 Apr; 18(4):288-94. PubMed ID: 7560811
    [Abstract] [Full Text] [Related]

  • 10. [Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period].
    Komaki T, Sakata S, Nakamura S, Matsuda M, Kojima N, Takuno H, Miura K.
    Nihon Naibunpi Gakkai Zasshi; 1989 Jul 20; 65(7):627-39. PubMed ID: 2583311
    [Abstract] [Full Text] [Related]

  • 11. Closer correlation between serum triiodothyronine and basal metabolic rate during antithyroid drug treatment in patients with Graves' disease.
    Hamada N, Miura T, Ban Y, Momotani N, Nishikawa Y, Ohno M, Morii H, Kitabatake S, Ito K.
    Endocrinol Jpn; 1978 Apr 20; 25(2):117-22. PubMed ID: 78844
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Thyroidal triiodothyronine and thyroxine in Graves' disease: correlation with presurgical treatment, thyroid status, and iodine content.
    Larsen PR.
    J Clin Endocrinol Metab; 1975 Dec 20; 41(06):1098-104. PubMed ID: 54364
    [Abstract] [Full Text] [Related]

  • 15. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease.
    Kallner G, Vitols S, Ljunggren JG.
    J Intern Med; 1996 Jun 20; 239(6):525-9. PubMed ID: 8656146
    [Abstract] [Full Text] [Related]

  • 16. Epithelial hyperplasia and decreased colloid content of the thyroid gland in triiodothyronine-predominant Graves' disease.
    Takamatsu J, Takeda K, Katayama S, Sakane S, Morita S, Kuma K, Ohsawa N.
    J Clin Endocrinol Metab; 1992 Oct 20; 75(4):1145-50. PubMed ID: 1400885
    [Abstract] [Full Text] [Related]

  • 17. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
    Roti E, Minelli R, Gardini E, Bianconi L, Salvi M, Gavaruzzi G, Ugolotti G, Braverman LE.
    J Clin Endocrinol Metab; 1994 Mar 20; 78(3):795-9. PubMed ID: 8126159
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves' disease: evidence against an immunosuppressive action of thionamide drugs.
    Wenzel KW, Lente JR.
    J Clin Endocrinol Metab; 1984 Jan 20; 58(1):62-9. PubMed ID: 6196375
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.